다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

IPN

Ipsen (IPN)

Ipsen SA

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:IPN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/07	21:55	GlobeNewswire Inc.	IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024	EU:IPN	Ipsen SA
2024/05/07	21:55	GlobeNewswire Inc.	Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting	EU:IPN	Ipsen SA
2024/05/07	01:00	GlobeNewswire Inc.	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	EU:IPN	Ipsen SA
2024/05/07	01:00	GlobeNewswire Inc.	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	EU:IPN	Ipsen SA
2024/05/02	14:30	GlobeNewswire Inc.	Ipsen appoints Keira Driansky as EVP, President of North America	EU:IPN	Ipsen SA
2024/05/02	14:30	GlobeNewswire Inc.	Ipsen appoints Keira Driansky as EVP, President of North America	EU:IPN	Ipsen SA
2024/05/02	14:30	GlobeNewswire Inc.	Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord	EU:IPN	Ipsen SA
2024/04/24	14:00	GlobeNewswire Inc.	Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	EU:IPN	Ipsen SA
2024/04/24	14:00	GlobeNewswire Inc.	Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	EU:IPN	Ipsen SA
2024/04/24	14:00	GlobeNewswire Inc.	Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024	EU:IPN	Ipsen SA
2024/04/22	14:00	GlobeNewswire Inc.	Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	EU:IPN	Ipsen SA
2024/04/22	14:00	GlobeNewswire Inc.	Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	EU:IPN	Ipsen SA
2024/04/22	14:00	GlobeNewswire Inc.	Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares	EU:IPN	Ipsen SA
2024/04/18	01:00	GlobeNewswire Inc.	Ipsen publishes its 2023 Universal Registration Document	EU:IPN	Ipsen SA
2024/04/18	01:00	GlobeNewswire Inc.	Ipsen publie son Document d’enregistrement universel 2023	EU:IPN	Ipsen SA
2024/04/09	01:00	GlobeNewswire Inc.	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	EU:IPN	Ipsen SA
2024/04/09	01:00	GlobeNewswire Inc.	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	EU:IPN	Ipsen SA
2024/04/02	14:00	GlobeNewswire Inc.	Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides	EU:IPN	Ipsen SA
2024/04/02	14:00	GlobeNewswire Inc.	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	EU:IPN	Ipsen SA
2024/04/02	14:00	GlobeNewswire Inc.	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	EU:IPN	Ipsen SA
2024/03/08	02:00	GlobeNewswire Inc.	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	EU:IPN	Ipsen SA
2024/03/08	02:00	GlobeNewswire Inc.	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	EU:IPN	Ipsen SA
2024/02/15	18:00	GlobeNewswire Inc.	Ipsen S.A. publie ses comptes consolidés 2023	EU:IPN	Ipsen SA
2024/02/15	18:00	GlobeNewswire Inc.	Ipsen S.A. publishes its 2023 Consolidated Financial Statements	EU:IPN	Ipsen SA
2024/02/14	06:08	GlobeNewswire Inc.	Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique	EU:IPN	Ipsen SA
2024/02/14	06:08	GlobeNewswire Inc.	Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA	EU:IPN	Ipsen SA
2024/02/14	06:08	GlobeNewswire Inc.	Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA	EU:IPN	Ipsen SA
2024/02/08	14:58	GlobeNewswire Inc.	Building on solid FY 2023 results, Ipsen anticipates four launches in 2024	EU:IPN	Ipsen SA
2024/02/08	14:58	GlobeNewswire Inc.	Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024.	EU:IPN	Ipsen SA
2024/02/08	14:58	GlobeNewswire Inc.	Building on solid FY 2023 results, Ipsen anticipates four launches in 2024	EU:IPN	Ipsen SA

검색 관련기사 보기:EU:IPN

1 2 3 4 5 6 7 8 9 10 다음 >>

Financial Select Sector

Verizon Communications

JP Morgan Chase

Invesco QQQ Trust Series 1

BNP Paribas (QX)

Deutsche Telekom (QX)

US Dollar vs Yen

US Dollar vs Euro

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관